REMERON

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Cyprus, Ecuador, Estonia, Germany, Hong Kong SAR China, Italy, Japan, Lithuania, Mexico, Netherlands, Romania, Singapore, South Africa, Turkey.

Active ingredients

The drug REMERON contains one active pharmaceutical ingredient (API):

1	Mirtazapine UNII A051Q2099Q - MIRTAZAPINE
	Mirtazapine is a centrally active presynaptic α2-antagonist, which increases central noradrenergic and serotonergic neurotransmission. The enhancement of serotonergic neurotransmission is specifically mediated via 5-HT1 receptors, because 5-HT2 and 5-HT3 receptors are blocked by mirtazapine. Both enantiomers of mirtazapine are presumed to contribute to the antidepressant activity, the S(+) enantiomer by blocking α2 and 5-HT2 receptors and the R(-) enantiomer by blocking 5-HT3 receptors.
	Read more about Mirtazapine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REMERON Tablet / Orally disintegrating tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AX11	Mirtazapine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	527303305111311, 527303306118318, 527303307114316, 527312070008303, 527312070008403
CA	Health Products and Food Branch	02243910, 02248542, 02248543, 02248544
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00781026, 00781032, 04196891
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2747-MEE-0517, 2875-MEE-0617
EE	Ravimiamet	1116829, 1116830, 1116841, 1116852, 1116863, 1116874, 1116885, 1116896, 1116908, 1116919, 1712089, 1722989, 1825310
HK	Department of Health Drug Office	51817, 52381
IT	Agenzia del Farmaco	029444181
JP	医薬品医療機器総合機構	1179051F1037, 1179051F2033
LT	Valstybinė vaistų kontrolės tarnyba	1004093, 1004094
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	303M2003
NL	Z-Index G-Standaard, PRK	61484, 61492, 67784
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68318001, W68318002, W68318003, W68318004, W68318005
SG	Health Sciences Authority	12526P, 12527P
TR	İlaç ve Tıbbi Cihaz Kurumu	8683280337404, 8683280337411
US	FDA, National Drug Code	0052-0105, 0052-0106, 0052-0107, 0052-0108, 0052-0110, 0052-4364, 0052-4365, 70518-2176
ZA	Health Products Regulatory Authority	32/1.2/0481, 32/1.2/0482